A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/436 (2006.01) A61K 9/00 (2006.01) A61K 31/277 (2006.01) A61K 38/55 (2006.01) A61K 47/30 (2006.01) A61K 47/42 (2006.01) A61K 47/48 (2006.01) A61M 1/14 (2006.01) A61B 17/11 (2006.01)
Patent
CA 2572963
The present invention describes various devices and methods wherein a cytostatic antiproliferative drug, either alone or in combination with other drugs, is placed between internal body tissues to prevent the formation of scar tissue and/or adhesions during healing of a wound or surgical site. Specific devices to achieve this administration include, but are not limited to, a permanent implant or a biodegradable material having an attached antiproliferative drug such as sirolimus. These antiproliferative drugs may be combined with other drugs including, but not limited to, antiplatelets, antithrombotics or anticoagulants. The present invention also contemplates methods to a reduce scar tissue and/or adhesions or adhesion formation at an anastomosis site. In particular, a cytostatic antiproliferative drug is administered to an arteriovenous shunt anastomoses in patients having end- stage renal disease.
La présente invention concerne divers dispositifs et méthodes, selon lesquels un médicament antiprolifératif cytostatique, seul ou combiné à d'autres médicaments, est placé entre des tissus corporels internes de manière à prévenir la formation de tissu cicatriciel ou d'adhésions, lors de la guérison d'une plaie ou d'un champ opératoire. Des dispositifs spécifiques permettant de réaliser cette administration comprennent, entres autres, un implant permanent ou une matière biodégradable possédant un médicament antiprolifératif attaché, tel que sirolimus. Ces médicaments antiprolifératifs peuvent être combinés à d'autres médicaments, entre autres, des antiplaquettaires, des antithrombotiques ou des anticoagulants. Ladite invention a aussi pour objet des méthodes permettant de diminuer un tissu cicatriciel et/ou des adhésions ou la formation d'adhésion au niveau d'un site d'anastomose. Notamment, un médicament antiprolifératif cytostatique est administré à une anastomose artério-veineuse chez des patients souffrant d'une insuffisance rénale terminale.
Fischell Tim A.
Luderer Jack R.
Shebuski Ronald J.
Afmedica Inc.
Smart & Biggar
LandOfFree
Combination drug therapy for reducing scar tissue formation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination drug therapy for reducing scar tissue formation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination drug therapy for reducing scar tissue formation will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1630782